NanoViricides, Inc. (NNVC) earnings
NNVC earnings moved a median of -2.67% by the close. Quarterly and annual NNVC reports and results, each read against the price at its own news timestamp. Back to the NNVC overview →
23 measured NNVC earnings events.
Where these NNVC earnings landedvs 23 measured NNVC earnings reactions
| Middle 50% of NNVC earnings reactions | -12.23% to +0.32% |
|---|---|
| Median reaction (to close) | -2.67% |
| Measured reactions | 23 |
Point-in-time · zero look-ahead
Half of the 23 NNVC earnings events with a measured close landed between -12.23% and +0.32%; 26% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials | Press release | -0.99% | -14.47% | |
| Form 10-K NANOVIRICIDES, INC. For: Jun 30 | SEC filing · Form 10-K | -0.99% | -14.47% | |
| Form 10-Q NANOVIRICIDES, INC. For: Mar 31 | SEC filing · Form 10-Q | -1.59% | -5.73% | |
| NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II | Press release | -1.59% | -5.73% | |
| Form 10-Q NANOVIRICIDES, INC. For: Dec 31 | SEC filing · Form 10-Q | +0.98% | +1.96% | |
| NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position | Press release | +0.67% | -2.67% | |
| Form 10-Q NANOVIRICIDES, INC. For: Sep 30 | SEC filing · Form 10-Q | +0.67% | -2.67% | |
| NanoViricides, Inc. Has Filed its Annual Report | Press release | +2.14% | +2.14% | |
| Form 10-K NANOVIRICIDES, INC. For: Jun 30 | SEC filing · Form 10-K | +2.14% | +2.14% | |
| NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu | Press release | +0.70% | -1.40% | |
| Form 10-Q NANOVIRICIDES, INC. For: Mar 31 | SEC filing · Form 10-Q | +0.70% | -1.40% | |
| NanoViricides, Inc. Has Filed its Quarterly Report | Press release | +0.76% | +1.48% | |
| Form 10-Q NANOVIRICIDES, INC. For: Dec 31 | SEC filing · Form 10-Q | -1.83% | -2.17% | |
| NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID | Press release | -2.13% | -12.14% | |
| Form 10-Q NANOVIRICIDES, INC. For: Sep 30 | SEC filing · Form 10-Q | -2.13% | -12.14% | |
| NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID | Press release | +5.04% | +7.91% | |
| Form 10-K NANOVIRICIDES, INC. For: Jun 30 | SEC filing · Form 10-K | +5.04% | +7.91% | |
| Form 10-Q NANOVIRICIDES, INC. For: Mar 31 | SEC filing · Form 10-Q | -5.33% | -20.00% | |
| NanoViricides Has Filed its Quarterly Report | Press release | -5.33% | -20.00% | |
| NanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon | Press release | -3.33% | -0.83% | |
| Form 10-Q NANOVIRICIDES, INC. For: Dec 31 | SEC filing · Form 10-Q | -3.33% | -0.83% | |
| NanoViricides Has Filed its Quarterly Report - NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications | Press release | -7.97% | -12.32% | |
| Form 10-Q NANOVIRICIDES, INC. For: Sep 30 | SEC filing · Form 10-Q | -7.97% | -12.32% |
Keep exploring
More NNVC: analyst actions → · SEC filings → · NNVC overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Minerva Neurosciences, Inc (NERV) | 164 | 0.00% | 48% |
| NIGHTSTAR THERAPEUTICS PLC AMERICAN DEPOSITARY SHA (NITE) | 164 | -0.04% | 28% |
| Matinas Biopharma Holdings, Inc. (MTNB) | 161 | -0.53% | 39% |
| NanoVibronix, Inc. (NAOV) | 161 | -0.40% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.